Rare disease candidates with surrogate endpoints are struggling to gain accelerated approval from FDA, most recently highlighted by the agency declining to grant Santhera Pharmaceuticals accelerated approval for its Duchene muscular dystrophy candidate Raxone (idebenone).
The decision will force the Swiss drugmaker to conduct another Phase III study of the drug, for which it expects...






